To assess potential differences between the efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab, in patients with vs without prior myocardial infarction (MI)/ischemic stroke.
To investigate associations for polymorphisms in β-carotene 9',10'-oxygenase (<i>BCO2</i>, rs10431036 and rs11214109), proprotein convertase subtilisin kexin type 9 (<i>PCSK9</i>, rs11583680), and tribbles pseudokinase 1 (<i>TRIB1</i>, rs17321515 and rs2954029), as well as lifestyle factors, with ischemic stroke (IS).
Proprotein convertase subtilisin-kexin type 9 inhibitors were associated with lower risk of MI (1.49 vs. 1.93 per 100 patient-year; RR 0.80, 95% CI 0.74-0.86; I2 = 0%; P < 0.0001), ischaemic stroke (0.44 vs. 0.58 per 100 patient-year; RR 0.78, 95% CI 0.67-0.89; I2 = 0%; P = 0.0005), and coronary revascularization (2.16 vs. 2.64 per 100 patient-year; RR 0.83, 95% CI 0.78-0.89; I2 = 0%; P < 0.0001), compared with the control group.